King’s Award for Enterprise for Stockport firm

Stockport based Seda Pharmaceutical Development Services is one of 252 firms across the UK to have won a King’s Award for Enterprise in 2024.

Seda has been recognised for its excellence in international trade, winning the King’s Award for Outstanding Short-Term Growth in overseas sales.

Seda CEO, Dr Paul Stott commented:

“We are absolutely delighted that Seda has been recognised with this most prestigious award.

“It is a testament to the exceptional service underpinned by scientific excellence that our team consistently delivers, which has been the key driver of our recent growth.

“Global partnerships now account for more than half of our business and based on our increasing global reach and enhanced service offering, we expect that share to grow significantly over the coming years.”

Based at Cheadle Royal, Seda supports biotech clients in the design, development and market approval of novel medicinal products in a wide range of therapeutic areas.

The company has made significant investment in premises, equipment and in the expansion and development of the team to enhance its offering and meet client demand. In late 2024, it will be opening a neighbouring state-of-the art manufacturing facility to supply products for evaluation in clinical trials. The King’s Award is the latest of several awarded to Seda for its commercial and technical achievements.

Representatives from Seda will attend an ceremony at Windsor Castle to accept the award from HRH King Charles III on 9th July.